AbbVie Inc (ABBV)vsAethlon Medical Inc (AEMD)
ABBV
AbbVie Inc
$286.40
-0.14%
HEALTHCARE · Cap: $504.37B
AEMD
Aethlon Medical Inc
$5.55
+9.47%
HEALTHCARE · Cap: $8.26M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 11212285% more annual revenue ($64.39B vs $574,240). ABBV leads profitability with a 9.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
AEMD
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.7%
Fair Value
$152.97
Current Price
$286.40
$133.43 premium
Margin of Safety
-69.9%
Fair Value
$1.23
Current Price
$5.55
$4.32 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 4278.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : AEMD
The strongest argument for AEMD centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 4278.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.
Bear Case : AEMD
The primary concerns for AEMD are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while AEMD is a hypergrowth play — different risk/reward profiles.
AEMD carries more volatility with a beta of 1.21 — expect wider price swings.
AEMD is growing revenue faster at 4278.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 39/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Aethlon Medical Inc
HEALTHCARE · MEDICAL DEVICES · USA
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life- and organ-threatening diseases in the United States. The company is headquartered in San Diego, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?